Michael Gladstone is a partner at Atlas Venture and focuses on building new therapeutics companies. Michael is a co-founder and board member of Diagonal Therapeutics and Third Harmonic Bio (NASDAQ: THRD), and a board member of Day One Biopharmaceuticals (NASDAQ: DAWN), Kailera Therapeutics, Pheon Therapeutics, and several stealth NewCos. Michael was previously a board director for Aiolos Bio (acquired by GSK) and Versanis Bio (acquired by Lilly). Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center where he led research on HIV vaccines with Harvard Medical School Professor Norman Letvin. Michael received an AB in biochemical sciences with highest honors from Harvard College.